Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBET: Bevacizumab + Erlotinib in EGFR-overamplified metastatic colorectal cancer
KCT0009473Phase 2Not yet recruiting
- Sponsor
- Korea University Anam Hospital
- Start
- Apr 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and erlotinib in metastatic colon cancer (mCRC), sponsored by Korea University Anam Hospital. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
bevacizumaberlotinib
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on KCT0009473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009473.